Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

José Mateus(La Jolla Institute for Immunology), Alba Grifoni(La Jolla Institute for Immunology), Alison Tarke(La Jolla Institute for Immunology), John Sidney(La Jolla Institute for Immunology), Sydney I. Ramirez(La Jolla Institute for Immunology), Jennifer M. Dan(La Jolla Institute for Immunology), Zoe C. Burger(University of California San Diego), Stephen A. Rawlings(University of California San Diego), Davey M. Smith(University of California San Diego), Elizabeth J. Phillips(Murdoch University), S. Mallal(Murdoch University), Marshall Lammers(La Jolla Institute for Immunology), Paul Rubiro(La Jolla Institute for Immunology), Lorenzo Quiambao(La Jolla Institute for Immunology), Aaron Sutherland(La Jolla Institute for Immunology), Esther Dawen Yu(La Jolla Institute for Immunology), Ricardo da Silva Antunes(La Jolla Institute for Immunology), Jason Greenbaum(La Jolla Institute for Immunology), April Frazier(La Jolla Institute for Immunology), Alena J. Markmann(University of North Carolina at Chapel Hill), Lakshmanane Premkumar(University of North Carolina at Chapel Hill), Aravinda de Silva(University of North Carolina at Chapel Hill), Bjoern Peters(La Jolla Institute for Immunology), Shane Crotty(La Jolla Institute for Immunology), Alessandro Sette(La Jolla Institute for Immunology), Daniela Weiskopf(La Jolla Institute for Immunology)
Science
August 4, 2020
Cited by 1,282Open Access
Full Text

Abstract

Preexisting immune response to SARS-CoV-2 Robust T cell responses to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus occur in most individuals with coronavirus disease 2019 (COVID-19). Several studies have reported that some people who have not been exposed to SARS-CoV-2 have preexisting reactivity to SARS-CoV-2 sequences. The immunological mechanisms underlying this preexisting reactivity are not clear, but previous exposure to widely circulating common cold coronaviruses might be involved. Mateus et al. found that the preexisting reactivity against SARS-CoV-2 comes from memory T cells and that cross-reactive T cells can specifically recognize a SARS-CoV-2 epitope as well as the homologous epitope from a common cold coronavirus. These findings underline the importance of determining the impacts of preexisting immune memory in COVID-19 disease severity. Science , this issue p. 89


Related Papers